It has been five years since the first biosimilar launched in the United States market—marking the first steps in expanding access to innovative biologic-based treatments that help patients
Patients in some European countries are waiting up to six times longer for access to medicines than their neighbours, according to a survey by Europe’s pharma trade body.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
